Today is the 73rd’s Children’s Day. On May 31, 2023, the Wuzhishan Branch of Jiusan Society, the branch of Hainan Women and Children's Medical Center and the Wuzhishan Disabled Persons' Federation co-sponsored the "Care for the Children, Walk with the Children" donation activity for exceptional children and thalassemia children to celebrate the Children’s Day, which was held in Wuzhishan Special Education School.
The 2022 People's Financial Summit Forum, hosted by www.people.cn online, was held in Beijing on Dec 29. The winners of the 19th People's Ingenuity Award were officially released at the forum. transformer Base Editor (tBE), which is developed by the scientific co-founders of CorrectSequence Therapeutics (Correctseq), won the Ingenuity Award for its higher editing efficiency and better safety in the whole genome and whole transcriptome, and promising to completely cure single base genetic diseases. Correctseq also became the only biotech pharmaceutical company to receive this award.
Recently, Dr. Xiaodun Mou, CEO of CorrectSequence Therapeutics, visited the "Dialogue 22" column of Oriental Financial Pudong Channel to share how to use creative gene editing technology to develop low-cost and high-quality therapy for people with severe diseases.
Nov 17-18, 2022, the 4th Bio-ONE Forum was hold in Shanghai. Mr. Edwin Lan, head of CMC-MFG, Ex vivo Platform of CorrectSequence Therapeutics (Correctseq), participated in the forum and made a speech titled CMC on ex vivo Platform.
Nov 10, 2022, Dr. Mou, CEO of Correctseq, won the Pharma Big Star prize of Annual Influential Enterprise Leaders of Chinese CGT Field in 2022 in Shanghai (Minhang) Biomedical Industry Innovation Summit Award Ceremony of 2022. The prize list was selected by MedClub of emedclub.com together with industry experts.
Oct 15, 2022, the Fourth Cell and Gene Therapy Non-Clinical Evaluation Salon organized by Drug Toxicology Committee of Chinese Pharmacological Society, Drug Toxicology and Safety Evaluation Committee of Chinese Society of Toxicology, and Tsinghua University, was successfully held online. The salon’s theme was Oncolytic Viruses, Gene Editing and R&D Cases. Dr. Mou, CEO of Correctseq, participated in the salon and made a speech titled How to Create Innovative Gene Editing System and Make Its Clinical Application Safety. The Chairman of Drug Toxicology and Safety Evaluation Committee of Chinese Society of Toxicology, Dr. Mingyang Liao participated in the salon and make an opening speech. The Chairman of the salon, Deputy Editor-in-Chief of Tsinghua University Press, Yu Sun, and the Chairman of the salon, Deputy Chairman and Secretary-General of Drug Toxicology and Safety Evaluation Committee of Chinese Society of Toxicology, Vice President of Suzhou Pharmaceutical Research Institute, Quanjun Wang hosted the salon.
On Aug 2-4, 2022, National Medical Products Administration Institute of Executive Development hold Drug Researcher Conference online. Dr Lijie Wang, head of CorrectSequence Therapeutics (Correctseq) Gene Editing Platform, was invited to attend the conference and made a speech on the topic of “the Latest Advances and Clinical Applications of Gene Editing”. (Online Live| Drug Researcher Conference( Topic: Biologics Registration Regulations and Applications)
July 13, 2022(USA time), tBE(transformer Base Editor), developed by the scientific co-founders of CorrectSequence Therapeutics(Correctseq), is authorized by USPTO formally(United States Patent and Trademark Office). It’s the Chinese first base editing tool authorized by overseas patents. Correctseq has got the worldwide exclusive license of tBE from ShanghaiTech University, becoming the exclusive biopharmaceutical company that owns the global rights and interests of the underlying platform-based base editing system patent. The First IND pipeline for thalassemia of Correctseq is well underway, using tBE to create a creative base editing therapy. Correctseq is the Chinese first biopharmaceutical company which transforms the Chinese self-developed base editing tool into a creative base editing therapy. Correctseq has already got the worldwide exclusive license of eBE, which is the first base editing tool authorized by Chinese patents. At the same time, Correctseq has applied PCT for several base editing tools.